ClinicalTrials.gg
RecruitingNCT07037888Updated Nov 6, 2026

Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy

A Phase 4 interventional study of Ketorolac and Control (Standard treatment) in Femoracetabular Impingement and Hip Arthroscopy, sponsored by Henry Ford Health System. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Henry Ford Health System · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Dec 2023, registered Jun 2025).
  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Nov 6, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Femoracetabular Impingement with a site in United States — 10 open to participants now, 15 under way, 1 of them phase 3. Femoracetabular Impingement · United States.

Planned enrollment
6th of 28
100 · median 62
Started
2023
with 4 others
Phase 4
6 of 37
2 open now
Primary completion
2026-12
later than 6 of 14 live
Registered
37th of 37
by date

Among the 37 studies in Femoracetabular Impingement with a site in United States, this one is the 6th largest by planned enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2023, is one of 6 in phase 4, reaches primary completion later than 6 of the 14 other live ones, and was the 37th registered.

Femoracetabular Impingement

116 studies on the registry are indexed under Femoracetabular Impingement; 37 are open to participants now.

Browse Femoracetabular Impingement studies →

Open to participants now

10 of the 37 studies in Femoracetabular Impingement with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Femoracetabular Impingement studies recruiting now, 6 (30%) set no upper age limit and 12 (60%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Femoracetabular Impingement with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether the medication ketorolac can help manage pain after hip arthroscopy as well or better than the standard opioid-based pain medications. This study focuses on adult patients (over 18 years old) undergoing hip arthroscopy at Henry Ford Health System in Detroit, Michigan. Both men and women are included, and all participants must be able to consent and communicate in English.

The main questions it aims to answer are:

Can ketorolac help control pain as effectively or better than opioids after hip arthroscopy?

Will ketorolac use reduce the amount of opioid medication needed after surgery?

Researchers will compare the group receiving ketorolac to the group receiving standard opioid pain medications to see if ketorolac reduces pain and opioid use after surgery.

Participants will:

Be randomly assigned to one of two groups:

The control group, which receives the current standard pain management protocol (hydrocodone-acetaminophen and diazepam)

The experimental group, which receives the same protocol plus ketorolac and a stomach-protecting medication (omeprazole)

Receive their assigned pain medications after hip arthroscopy

Be asked to:

Take the prescribed medications after discharge

Complete a pain journal for 5 days following surgery, documenting pain levels and any side effects

Complete follow-up surveys and assessments at 2 weeks, 6 weeks, and 3 months after surgery

The main measurement researchers will use is the Visual Analog Scale (VAS) for pain on post-operative day 4. Additional measures include how many narcotic pills are used and results from PROMIS physical function and pain interference scores.

The hope is that ketorolac will provide equal or better pain control without the risks of addiction and side effects associated with opioid medications. If successful, this approach could offer a safer alternative for managing pain after hip arthroscopy. Participants may personally benefit by having effective pain relief with fewer risks, and future patients could benefit from improved pain management options.

03

Conditions studied

  • Femoracetabular Impingement
  • Hip Arthroscopy

Keywords

  • Sports Medicine
  • Hip Arthroscopy
  • FAI
  • Opioids
  • Ketorolac
  • Multi-modal pain
04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing hip arthroscopy over the age of 18 with Dr. T. Sean Lynch
  • Diagnosis of femoroacetabular impingement (FAI)

Exclusion criteria

Exclusion Criteria:

  • Patients with inability to consent and/or do not speak English
  • Patients with conditions with NSAIDs (medication allergy, peptic ulcer disease, bleeding diathesis, and renal disease)
  • Patients with history of drug and alcohol use disorder
  • Patients with chronic analgesia (filled two opioid prescriptions within 6 months of the surgery)
  • Patients with psychotropic medication usage
  • Patients who take pentoxifylline, probonecid, aspirin, and/or NSAIDs who cannot stop taking it for the study
  • Patients who are not discharged same day after surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    Control

    The standard of care/control pain protocol

    Drug: Control (Standard treatment)

  • Active comparator
    Ketorolac

    Intra-operative IV and Oral doses of Ketorolac plus Standard of care

    Drug: Ketorolac · Drug: Control (Standard treatment) · Drug: Omeprazole

Interventions

  • IV ketorolac intraoperative loading dose Ketorolac 10mg 1 tablet q6hrs to start on POD0

  • DrugControl (Standard treatment)

    hydrocodone-acetaminophen 5mg/325mg 1 tablet q6hrs PRN to start on POD0 30 tablets

  • DrugControl (Standard treatment)

    indomethacin 75mg 1 tablet QD to start on POD0 10 tablets

  • DrugControl (Standard treatment)

    diazepam 5mg 1-2 tablets q8hrs PRN to start on POD0 15 tablets

  • 20 mg qd

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale (VAS)

    A validated tool used to help a person rate the intensity of certain sensations and feelings, such as pain. The visual analog scale for pain is a straight line with the far-left end meaning no pain and the far-right end meaning the worst pain imaginable. A patient marks a point on the line that matches the amount of pain he or she feels. It may be used to help choose the right dose of pain medicine.

    Time frame: 5 days

Secondary outcomes

  1. PROMOIS- PF

    This is a standardized patient-reported outcome measure that assesses an individual's self-reported capability to perform physical activities, including both basic activities of daily living (ADLs) and instrumental activities of daily living (IADLs). It utilizes a T-score scale, mean = 50, standard deviation = 10, and higher scores indicate greater physical function.

    Time frame: 2 weeks, 6 weeks, 3 months

  2. PROMOIS- PI

    a patient-reported outcome measure that assesses the extent to which pain hinders a person's engagement in various activities. It utilizes a T-score scale, mean = 50, standard deviation = 10, and higher scores indicate greater interference from pain.

    Time frame: 2 weeks, 6 weeks, 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bloom DA, Kirby DJ, Thompson K, Baron SL, Chee C, Youm T. Effect of Acetaminophen on Postoperative Percocet Use In Hip Arthroscopy: A Randomized Controlled Trial. Arthroscopy. 2021 Feb;37(2):530-536. doi: 10.1016/j.arthro.2020.09.046. Epub 2020 Oct 10. PubMed 33045334 ↗
  • Moutzouros V, Jildeh TR, Tramer JS, Meta F, Kuhlmann N, Cross A, Okoroha KR. Can We Eliminate Opioids After Anterior Cruciate Ligament Reconstruction? A Prospective, Randomized Controlled Trial. Am J Sports Med. 2021 Dec;49(14):3794-3801. doi: 10.1177/03635465211045394. Epub 2021 Oct 20. PubMed 34668795 ↗
  • Jildeh TR, Abbas MJ, Hasan L, Moutzouros V, Okoroha KR. Multimodal Nonopioid Pain Protocol Provides Better or Equivalent Pain Control Compared to Opioid Analgesia Following Arthroscopic Rotator Cuff Surgery: A Prospective Randomized Controlled Trial. Arthroscopy. 2022 Apr;38(4):1077-1085. doi: 10.1016/j.arthro.2021.11.028. Epub 2021 Nov 25. PubMed 34838987 ↗
  • LaPorte C, Rahl MD, Ayeni OR, Menge TJ. Postoperative Pain Management Strategies in Hip Arthroscopy. Curr Rev Musculoskelet Med. 2019 Dec;12(4):479-485. doi: 10.1007/s12178-019-09579-x. PubMed 31650392 ↗
  • Kahlenberg CA, Patel RM, Knesek M, Tjong VK, Sonn K, Terry MA. Efficacy of Celecoxib for Early Postoperative Pain Management in Hip Arthroscopy: A Prospective Randomized Placebo-Controlled Study. Arthroscopy. 2017 Jun;33(6):1180-1185. doi: 10.1016/j.arthro.2017.01.016. Epub 2017 Mar 1. PubMed 28258773 ↗
  • Beck EC, Nwachukwu BU, Jan K, Krivicich LM, Chahla J, Fu MC, Nho SJ. The Effect of Postoperative Opioid Prescription Refills on Achieving Meaningful Clinical Outcomes After Hip Arthroscopy for Femoroacetabular Impingement Syndrome. Arthroscopy. 2020 Jun;36(6):1599-1607. doi: 10.1016/j.arthro.2020.02.007. Epub 2020 Feb 14. PubMed 32061972 ↗
  • Jamil M, Dandachli W, Noordin S, Witt J. Hip arthroscopy: Indications, outcomes and complications. Int J Surg. 2018 Jun;54(Pt B):341-344. doi: 10.1016/j.ijsu.2017.08.557. Epub 2017 Aug 18. PubMed 28823795 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 26, 2025
StartActual
Dec 13, 2023
Primary completionEst.
Dec 2026was Sep 2026
CompletionEst.
Dec 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Dec 2026
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Sep 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07037888
Responsible party
Thomas Lynch (Sports Medicine Orthopedic Surgeon, Henry Ford Health System) — Principal investigator
First posted
Jun 26, 2025
Start date
Dec 13, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketorolac · Omeprazole

Start the discussion